Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study

Fig. 1. Percent change from baseline in UACR at 24 weeks after randomization (in all patients and stratified by concomitant ACE-I/ARB use). ACE-I angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blocker, CI confidence interval, LOCF last observation carried forward, LS least squares, UACR urine albumin to creatine ratio

Fig. 2. a UACR remission rate at each time point up to 52 weeks after randomization. UACR urine albumin to creatine ratio. Placebo group data from the 24-week dose–response study only. Apararenone treatment data from the 24-week dose–response study and the 28-week extension study. b Time-course of percent changes from baseline in UACR up to 52 weeks after randomization. CI confidence interval, FU follow-up, UACR urine albumin to creatine ratio. Geometric LS mean (95% CI). Placebo group data from the 24-week dose–response study only. Apararenone treatment data from the 24-week dose–response study and the 28-week extension study

Fig. 3. Change in blood pressure at 24 weeks after randomization (in all patients and stratified by baseline SBP and DBP). Mean (standard deviation). DBP diastolic blood pressure, SBP systolic blood pressure

Fig. 4. Time-course of percent changes from baseline in eGFR up to 52 weeks after randomization. eGFR estimated glomerular filtration rate, FU follow-up, SD standard deviation, Q1 first quartile, Q3 third quartile. Median (Q1/Q3). Placebo group data from the 24-week dose–response study only. Apararenone treatment data from the 24-week dose–response study and the 28-week extension study

Fig. 5. Time-course of changes from baseline in serum potassium level (measured at a central laboratory) up to 52 weeks after randomization. Mean (95% CI). CI confidence interval, FU follow-up, SD standard deviation. Placebo group data from the 24-week dose–response study only. Apararenone treatment data from the 24-week dose–response study and the 28-week extension study